Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.211
Sell
RSI(14)
46.953
Neutral
STOCH(KDJ)(9,3,3)
64.570
Buy
ATR(14)
1.199
Low Volatility
CCI(14)
36.314
Neutral
Williams %R
46.778
Neutral
TRIX(12,20)
-0.351
Sell
StochRSI(14)
79.164
Sell
GSK plc
GSK53.940USD
-0.760-1.39%
Close 03/26, 16:00（ET）Quotes delayed by 15 min
109.91BMarket Cap
14.51P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of GSK plc
Currency: USD Updated: 2026-03-26Key Insights
GSK plc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 56 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 53.11.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
GSK plc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
GSK plc Highlights
StrengthsRisks
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 43.02B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 96.66%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 96.66%.
Fairly Valued
The company’s latest PE is 14.51, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 391.56M shares, decreasing 5.28% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 44.67K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.27.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
53.115
Target Price
+0.31%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-26The current financial score of GSK plc is 8.60, ranking 39 out of 157 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 11.46B, representing a year-over-year increase of 10.24%, while its net profit experienced a year-over-year increase of 59.51%.
Score
Financials
5.42
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.88
Operational Efficiency
10.00
Growth Potential
9.42
Shareholder Returns
8.28
GSK plc's Company Valuation
Currency: USD Updated: 2026-03-26The current valuation score of GSK plc is 6.15, ranking 129 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 14.51, which is 79.89% below the recent high of 26.11 and 74.79% above the recent low of 3.66.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 56/157
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-26The current earnings forecast score of GSK plc is 7.20, ranking 108 out of 157 in the Pharmaceuticals industry. The average price target is 45.30, with a high of 56.23 and a low of 34.26.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
53.115
Target Price
+0.31%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
GSK plc
GSK
10
Biogen Inc
BIIB
37
Amgen Inc
AMGN
36
Eli Lilly and Co
LLY
35
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
32
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-26The current price momentum score of GSK plc is 7.24, ranking 40 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 58.35 and the support level at 50.54, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
53.084
Buy
MA10
53.042
Buy
MA20
54.589
Sell
MA50
54.831
Sell
MA100
51.567
Buy
MA200
45.906
Buy
Institutional Confidence
Currency: USD Updated: 2026-03-26The current institutional shareholding score of GSK plc is 3.00, ranking 93 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 19.21%, representing a quarter-over-quarter increase of 0.38%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 68.52M shares, representing 3.37% of shares outstanding, with 12.21% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
JTC Employer Solutions Trusteee Ltd
Wellington Management Company, LLP
Fidelity Institutional Asset Management
Holocene Advisors, LP
T. Rowe Price International Ltd
1
2
Risk Assessment
Currency: USD Updated: 2026-03-26The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of GSK plc is 9.75, ranking 6 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.48
VaR
+2.17%
240-Day Maximum Drawdown
+15.27%
240-Day Volatility
+25.45%
Return
Best Daily Return
60 days
+7.29%
120 days
+7.29%
5 years
+33.42%
Worst Daily Return
60 days
-3.29%
120 days
-5.05%
5 years
-8.69%
Sharpe Ratio
60 days
+1.48
120 days
+1.45
5 years
+0.63
Risk Assessment
Maximum Drawdown
240 days
+15.27%
3 years
+29.93%
5 years
+39.91%
Return-to-Drawdown Ratio
240 days
+3.97
3 years
+0.54
5 years
+0.15
Skewness
240 days
+0.15
3 years
+0.11
5 years
+5.69
Volatility
Realised Volatility
240 days
+25.45%
5 years
+23.72%
Standardised True Range
240 days
+1.71%
5 years
+1.30%
Downside Risk-Adjusted Return
120 days
+239.38%
240 days
+239.38%
Maximum Daily Upside Volatility
60 days
+26.29%
Maximum Daily Downside Volatility
60 days
+25.94%
Liquidity
Average Turnover Rate
60 days
+0.12%
120 days
+0.12%
5 years
--
Turnover Deviation
20 days
-26.84%
60 days
+9.50%
120 days
+17.52%
Peer Comparison
Pharmaceuticals
GSK plc
GSK
7.24 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.73 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
